Want to see TSE:MRVL full AI Analyst Report?
MRVL Stock Chart & Stats
C$0.14
-C$0.01(-6.45%)
At close: 4:00 PM EST
C$0.14
-C$0.01(-6.45%)
Day’s Range― - ―
52-Week RangeC$0.12 - C$0.40
Previous CloseN/A
Volume5.00K
Average Volume (3M)89.38K
Market Cap
C$9.45M
Enterprise ValueC$13.07M
Total Cash (Recent Filing)C$434.80K
Total Debt (Recent Filing)C$1.40M
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding63,028,290
10 Day Avg. Volume75,294
30 Day Avg. Volume89,378
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash Burn (TTM)Trailing-twelve-month cash burn improved versus the prior year, indicating operating discipline that can extend runway absent new revenue. This durable improvement reduces immediate financing pressure and gives management more time to pursue development or strategic options.
Debt Reduced From 2025 LevelsTotal debt has declined from 2025 levels, improving leverage metrics and modestly enhancing financial flexibility. Lower debt lessens interest and refinancing burden over the medium term, helping reduce default risk and supporting strategic choices without immediate recapitalization.
Lean Operating Structure (small Headcount)A very small workforce suggests a low fixed-cost base and a lean operating model, which helps conserve cash and extend runway while management progresses R&D or partnership talks. This structural efficiency supports survival during long development cycles typical in biotech.
Bears Say
No Revenue BaseThe company reports no revenue and sustained operating losses, meaning it lacks an independent cash-generating business. Over the medium term this forces reliance on external capital, prevents self-funding of growth, and leaves execution contingent on successful financing or M&A.
Negative Shareholders' EquityNegative shareholders' equity reflects accumulated losses and a thin capital cushion, which limits access to traditional credit and increases the likelihood of equity dilution or recapitalization. This structural weakness constrains strategic options and raises solvency sensitivity.
Persistent Negative Free Cash FlowOperating and free cash flow remain negative across reporting periods, signaling ongoing cash burn. Persistent negative FCF necessitates recurring financing, creating dilution risk and restricting ability to invest in R&D or partnerships without external funding over the medium term.
Marvel Biosciences Corp News
MRVL FAQ
What was Marvel Biosciences Corp’s price range in the past 12 months?
Marvel Biosciences Corp lowest stock price was C$0.12 and its highest was C$0.40 in the past 12 months.
What is Marvel Biosciences Corp’s market cap?
Marvel Biosciences Corp’s market cap is C$9.45M.
When is Marvel Biosciences Corp’s upcoming earnings report date?
Marvel Biosciences Corp’s upcoming earnings report date is Nov 26, 2026 which is in 128 days.
How were Marvel Biosciences Corp’s earnings last quarter?
Marvel Biosciences Corp released its earnings results on Jun 18, 2026. The company reported C$0.007 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.007.
Is Marvel Biosciences Corp overvalued?
According to Wall Street analysts Marvel Biosciences Corp’s price is currently Overvalued.
Does Marvel Biosciences Corp pay dividends?
Marvel Biosciences Corp does not currently pay dividends.
What is Marvel Biosciences Corp’s EPS estimate?
Marvel Biosciences Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marvel Biosciences Corp have?
Marvel Biosciences Corp has 63,028,290 shares outstanding.
What happened to Marvel Biosciences Corp’s price movement after its last earnings report?
Marvel Biosciences Corp reported an EPS of C$0.007 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 8.333%.
Which hedge fund is a major shareholder of Marvel Biosciences Corp?
Currently, no hedge funds are holding shares in TSE:MRVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marvel Biosciences Corp
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer’s disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.